Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

1.

Phosphatidylserine-Liposomes Promote Tolerogenic Features on Dendritic Cells in Human Type 1 Diabetes by Apoptotic Mimicry.

Rodriguez-Fernandez S, Pujol-Autonell I, Brianso F, Perna-Barrull D, Cano-Sarabia M, Garcia-Jimeno S, Villalba A, Sanchez A, Aguilera E, Vazquez F, Verdaguer J, Maspoch D, Vives-Pi M.

Front Immunol. 2018 Feb 14;9:253. doi: 10.3389/fimmu.2018.00253. eCollection 2018.

2.

Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization.

Fuchs A, Gliwiński M, Grageda N, Spiering R, Abbas AK, Appel S, Bacchetta R, Battaglia M, Berglund D, Blazar B, Bluestone JA, Bornhäuser M, Ten Brinke A, Brusko TM, Cools N, Cuturi MC, Geissler E, Giannoukakis N, Gołab K, Hafler DA, van Ham SM, Hester J, Hippen K, Di Ianni M, Ilic N, Isaacs J, Issa F, Iwaszkiewicz-Grześ D, Jaeckel E, Joosten I, Klatzmann D, Koenen H, van Kooten C, Korsgren O, Kretschmer K, Levings M, Marek-Trzonkowska NM, Martinez-Llordella M, Miljkovic D, Mills KHG, Miranda JP, Piccirillo CA, Putnam AL, Ritter T, Roncarolo MG, Sakaguchi S, Sánchez-Ramón S, Sawitzki B, Sofronic-Milosavljevic L, Sykes M, Tang Q, Vives-Pi M, Waldmann H, Witkowski P, Wood KJ, Gregori S, Hilkens CMU, Lombardi G, Lord P, Martinez-Caceres EM, Trzonkowski P.

Front Immunol. 2018 Jan 15;8:1844. doi: 10.3389/fimmu.2017.01844. eCollection 2017.

3.

Prenatal Administration of Betamethasone Causes Changes in the T Cell Receptor Repertoire Influencing Development of Autoimmunity.

Gieras A, Gehbauer C, Perna-Barrull D, Engler JB, Diepenbruck I, Glau L, Joosse SA, Kersten N, Klinge S, Mittrücker HW, Friese MA, Vives-Pi M, Tolosa E.

Front Immunol. 2017 Nov 13;8:1505. doi: 10.3389/fimmu.2017.01505. eCollection 2017.

4.

Expression of REG family genes in human inflammatory bowel diseases and its regulation.

Tsuchida C, Sakuramoto-Tsuchida S, Taked M, Itaya-Hironaka A, Yamauchi A, Misu M, Shobatake R, Uchiyama T, Makino M, Pujol-Autonell I, Vives-Pi M, Ohbayashi C, Takasawa S.

Biochem Biophys Rep. 2017 Oct 23;12:198-205. doi: 10.1016/j.bbrep.2017.10.003. eCollection 2017 Dec.

5.

Remission Phase in Paediatric Type 1 Diabetes: New Understanding and Emerging Biomarkers.

Fonolleda M, Murillo M, Vázquez F, Bel J, Vives-Pi M.

Horm Res Paediatr. 2017;88(5):307-315. doi: 10.1159/000479030. Epub 2017 Aug 3. Review.

6.

Liposome-based immunotherapy against autoimmune diseases: therapeutic effect on multiple sclerosis.

Pujol-Autonell I, Mansilla MJ, Rodriguez-Fernandez S, Cano-Sarabia M, Navarro-Barriuso J, Ampudia RM, Rius A, Garcia-Jimeno S, Perna-Barrull D, Martinez-Caceres E, Maspoch D, Vives-Pi M.

Nanomedicine (Lond). 2017 Jun;12(11):1231-1242. doi: 10.2217/nnm-2016-0410.

PMID:
28593827
7.

Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis.

Stojanovic I, Dimitrijevic M, Vives-Pi M, Mansilla MJ, Pujol-Autonell I, Rodríguez-Fernandez S, Palova-Jelínkova L, Funda DP, Gruden-Movsesijan A, Sofronic-Milosavljevic L, Hilkens CMU, Martinez-Caceres E, Miljkovic D.

Curr Pharm Des. 2017;23(18):2623-2643. doi: 10.2174/1381612823666170214120708. Review.

PMID:
28201972
8.

Clinical-scale expansion of CD34+ cord blood cells amplifies committed progenitors and rapid scid repopulation cells.

Casamayor-Genescà A, Pla A, Oliver-Vila I, Pujals-Fonts N, Marín-Gallén S, Caminal M, Pujol-Autonell I, Carrascal J, Vives-Pi M, Garcia J, Vives J.

N Biotechnol. 2017 Mar 25;35:19-29. doi: 10.1016/j.nbt.2016.10.011. Epub 2016 Oct 31.

PMID:
27810336
9.

Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies.

Lord P, Spiering R, Aguillon JC, Anderson AE, Appel S, Benitez-Ribas D, Ten Brinke A, Broere F, Cools N, Cuturi MC, Diboll J, Geissler EK, Giannoukakis N, Gregori S, van Ham SM, Lattimer S, Marshall L, Harry RA, Hutchinson JA, Isaacs JD, Joosten I, van Kooten C, Lopez Diaz de Cerio A, Nikolic T, Oral HB, Sofronic-Milosavljevic L, Ritter T, Riquelme P, Thomson AW, Trucco M, Vives-Pi M, Martinez-Caceres EM, Hilkens CMU.

PeerJ. 2016 Aug 30;4:e2300. doi: 10.7717/peerj.2300. eCollection 2016.

10.

The G1/S Specific Cyclin D2 Is a Regulator of HIV-1 Restriction in Non-proliferating Cells.

Badia R, Pujantell M, Riveira-Muñoz E, Puig T, Torres-Torronteras J, Martí R, Clotet B, Ampudia RM, Vives-Pi M, Esté JA, Ballana E.

PLoS Pathog. 2016 Aug 19;12(8):e1005829. doi: 10.1371/journal.ppat.1005829. eCollection 2016 Aug.

11.

CD26/DPPIV inhibition alters the expression of immune response-related genes in the thymi of NOD mice.

Julián MT, Alonso N, Colobran R, Sánchez A, Miñarro A, Pujol-Autonell I, Carrascal J, Rodríguez-Fernández S, Ampudia RM, Vives-Pi M, Puig-Domingo M.

Mol Cell Endocrinol. 2016 May 5;426:101-12. doi: 10.1016/j.mce.2016.02.014. Epub 2016 Feb 18.

12.

B-cell anergy induces a Th17 shift in a novel B lymphocyte transgenic NOD mouse model, the 116C-NOD mouse.

Carrascal J, Carrillo J, Arpa B, Egia-Mendikute L, Rosell-Mases E, Pujol-Autonell I, Planas R, Mora C, Mauricio D, Ampudia RM, Vives-Pi M, Verdaguer J.

Eur J Immunol. 2016 Mar;46(3):593-608. doi: 10.1002/eji.201445376. Epub 2016 Jan 12.

13.

Type 1 Diabetes Prevention in NOD Mice by Targeting DPPIV/CD26 Is Associated with Changes in CD8⁺T Effector Memory Subset.

Alonso N, Julián MT, Carrascal J, Colobran R, Pujol-Autonell I, Rodriguez-Fernández S, Teniente A, Fernández MA, Miñarro A, Ruiz de Villa MC, Vives-Pi M, Puig-Domingo M.

PLoS One. 2015 Nov 10;10(11):e0142186. doi: 10.1371/journal.pone.0142186. eCollection 2015.

14.

What potential is there for liposomal-based nanotherapy for the treatment of Type 1 diabetes?

Vives-Pi M, Pujol-Autonell I.

Nanomedicine (Lond). 2015 Oct;10(19):2955-2958. doi: 10.2217/nnm.15.140. Epub 2015 Sep 30. No abstract available.

15.

Innovative immunological strategies for type 1 diabetes.

Vives-Pi M, Pujol-Autonell I.

Endocrinol Nutr. 2015 Nov;62(9):419-21. doi: 10.1016/j.endonu.2015.07.003. Epub 2015 Sep 3. English, Spanish. No abstract available.

PMID:
26342847
16.

Use of autoantigen-loaded phosphatidylserine-liposomes to arrest autoimmunity in type 1 diabetes.

Pujol-Autonell I, Serracant-Prat A, Cano-Sarabia M, Ampudia RM, Rodriguez-Fernandez S, Sanchez A, Izquierdo C, Stratmann T, Puig-Domingo M, Maspoch D, Verdaguer J, Vives-Pi M.

PLoS One. 2015 Jun 3;10(6):e0127057. doi: 10.1371/journal.pone.0127057. eCollection 2015.

17.

How apoptotic β-cells direct immune response to tolerance or to autoimmune diabetes: a review.

Vives-Pi M, Rodríguez-Fernández S, Pujol-Autonell I.

Apoptosis. 2015 Mar;20(3):263-72. doi: 10.1007/s10495-015-1090-8. Review.

18.

Maternal microchimerism: friend or foe in type 1 diabetes?

Ye J, Vives-Pi M, Gillespie KM.

Chimerism. 2014;5(2):21-3. Review.

19.

Maternal microchimerism: increased in the insulin positive compartment of type 1 diabetes pancreas but not in infiltrating immune cells or replicating islet cells.

Ye J, Vives-Pi M, Gillespie KM.

PLoS One. 2014 Jan 31;9(1):e86985. doi: 10.1371/journal.pone.0086985. eCollection 2014.

20.

Efferocytosis promotes suppressive effects on dendritic cells through prostaglandin E2 production in the context of autoimmunity.

Pujol-Autonell I, Ampudia RM, Planas R, Marin-Gallen S, Carrascal J, Sanchez A, Marin A, Puig-Domingo M, Pujol-Borrell R, Verdaguer J, Vives-Pi M.

PLoS One. 2013 May 15;8(5):e63296. doi: 10.1371/journal.pone.0063296. Print 2013.

Supplemental Content

Loading ...
Support Center